Recognizing its diagnostic potential, the NephroCheckTM test, which quantifies the product of [TIMP-2] × [IGFBP7], was approved by the U.S. Food and Drug Administration (FDA) in 2014 for clinical use in intensive care unit (ICU) settings to assess the risk of developing moderate to severe AKI [69]. Here, IGFBP7 is linked to acute kidney injury.